Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer

Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2-Positive Breast Cancer

Conclusion: The research suggests that subcutaneous trastuzumab is comparable in effectiveness and safety to the intravenous administration. Regional-specific studies may provide valuable insights into demographic factors influencing treatment outcomes in Peru or other countries. Furthermore, it cou...

Full description

Saved in:

Bibliographic Details
Main Authors:	Iris Otoya, Natalia Valdiviezo, Zaida Morante, Cindy Calle, Yomali Ferreyra, Norma Huarcaya-Chombo, Gabriela Polo-Mendoza, Carlos Castañeda, Tatiana Vidaurre, Silvia P. Neciosup, Mónica J. Calderón, Henry L. Gomez
Format:	Article
Language:	English
Published:	Wiley 2024-01-01
Series:	International Journal of Breast Cancer
Online Access:	http://dx.doi.org/10.1155/2024/9551710
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Experience of HER2-Positive Advanced Breast Cancer (ABC) Treatment and Evaluation of Blood Biomarkers in a Public Institution in Latin America (LATAM)
by: Guillermo Valencia, et al.
Published: (2025-05-01)

Primary Mediastinal Germ Cell Tumor With Bone Marrow Infiltration: A Case Report and Literature Review
by: Patricia Rioja, et al.
Published: (2025-07-01)

First-Line (1L) Treatment Decision Patterns and Survival of Hormone Receptor (HR)-Positive/HER2-Negative Advanced Breast Cancer (ABC) Patients in a Latin American (LATAM) Public Institution
by: Guillermo Valencia, et al.
Published: (2024-12-01)

Cost minimization analysis of treatments for metastatic HER2-positive breast cancer in Peru: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injections
by: Miguel Figallo, et al.
Published: (2024-01-01)

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan
by: Negar Pourjamal, et al.
Published: (2025-03-01)

Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
by: Gabriel L. Fiszman, et al.
Published: (2011-01-01)

Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?
by: Yu Ishimine, et al.
Published: (2015-01-01)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
by: Scott A Wu, et al.
Published: (2023-09-01)

Trastuzumab deruxtecan: A quantum leap in HER2-positive breast cancer
by: Manikandan Dhanushkodi
Published: (2019-01-01)

PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer
by: Xin Zhao, et al.
Published: (2025-04-01)

Trastuzumab Deruxtecan for HER2-Positive Breast Cancer with Central Nervous System Metastasis
by: Hiroaki Yamane, et al.
Published: (2024-12-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

Involvement of microRNAs-449/FASN axis in response to trastuzumab therapy in HER2-positive breast cancer
by: Ana Lameirinhas, et al.
Published: (2025-03-01)

Effect of HER2 Ile655Val polymorphism on the response to trastuzumab treatment in HER2-positive breast cancer patients
by: Zohreh Gheibipour, et al.
Published: (2025-07-01)

Trastuzumab Rechallenge in HER2-Positive Metastatic Breast Cancer: A Promising Strategy for Enhanced Progression-Free Survival Post Ado-Trastuzumab Emtansine Progression
by: Yunus Emre Altıntaş, et al.
Published: (2024-12-01)

Correlation between CTMP expression levels and resistance to trastuzumab in HER2 + metastatic breast cancer
by: Mania Makhoul, et al.
Published: (2025-07-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial
by: Mark Hensley, et al.
Published: (2025-07-01)

DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer
by: Xi Li, et al.
Published: (2025-03-01)

Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma
by: Michael Kim, et al.
Published: (2025-08-01)

Notch and Hedgehog Signalling Axis Drive Senescence in HER2-Positive Breast Cancer Resistant to Trastuzumab
by: Asiye Büşra Boz Er, et al.
Published: (2024-12-01)

A Case of Ventricular Arrhythmia in a Patient With HER2-Positive Gastric Cancer Receiving Trastuzumab
by: Naoto Takahashi, et al.
Published: (2025-01-01)

Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report
by: Hiromi Nagata, et al.
Published: (2020-01-01)

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review
by: I. V. Kolyadina
Published: (2023-10-01)

Prognostic Significance of Delays in Initiation of Adjuvant Trastuzumab-Based Therapy in Patients with HER2-Positive Breast Cancer
by: Gavin P. Dowling, et al.
Published: (2025-05-01)

PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer.
by: Daphne Gschwantler-Kaulich, et al.
Published: (2017-01-01)

Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report
by: Dalila Incognito, et al.
Published: (2025-06-01)

Trastuzumab deruxtecan for the late lines of treatment for HER2-low metastatic breast cancer: a clinical case
by: R. A. Murashko, et al.
Published: (2025-03-01)

Achievement of complete morphological regression in the use of trastuzumab in patients with inoperable locally advanced Her-2+ breast cancer
by: K. R. Zeinalova, et al.
Published: (2014-07-01)

Investigation of <i>ITGB3</i> Heterogeneity to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer
by: Asiye Busra Boz Er
Published: (2024-12-01)

HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
by: Rodrigo Sánchez-Bayona, et al.
Published: (2025-04-01)

Pharmacokinetic bioequivalence of the fixed-dose combination of pertuzumab and trastuzumab administered subcutaneously using a handheld syringe or an on-body delivery system
by: Chris Wynne, et al.
Published: (2025-06-01)

Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01)

Efficacy and safety of trastuzumab deruxtecan in Chinese patients with HER2-positive and HER2-low advanced breast cancer: a multicenter, observational, real-world study
by: Die Sang, et al.
Published: (2025-02-01)

Cardiac Toxicity Under Concurrent Administration of Trastuzumab (Anti‐HER2 Therapy) and Radiotherapy: Systematic Review and Meta‐Analysis
by: Ali Jabbari, et al.
Published: (2025-06-01)

Trastuzumab Duocarmazine in Pretreated Her2-Positive Breast Cancer: Has the “TULIP” Bloomed a Bit Too Late?
by: Akhil Santhosh
Published: (2025-08-01)

Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine
by: Sila Oksuz, et al.
Published: (2025-04-01)

Hedgehog inhibitors exert anti-proliferation effects and synergistically interact with trastuzumab in HER2-positive gastric cancer models
by: Zixin Yang, et al.
Published: (2025-05-01)

TRACKING HER2 TRAFFICKING AND ORGANELLE CROSSTALK IN TRASTUZUMAB-DERUXTECAN–TREATED BREAST CANCER CELLS USING MULTIMODAL IMAGING
Published: (2025-08-01)

Trastuzumab emtansine in locally advanced or metastatic HER2 positive breast cancer; GENESIS-SEFH drug evaluation report
by: Patricia Miranda Romero, et al.
Published: (2015-02-01)